Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)

PHASE2CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

October 26, 2017

Primary Completion Date

July 29, 2020

Study Completion Date

September 13, 2023

Conditions
Squamous Cell Carcinoma
Interventions
BIOLOGICAL

Pembrolizumab

IV infusion

Trial Locations (59)

2480

Lismore Base Hospital ( Site 0402), Lismore

2500

Southern Medical Day Care Centre ( Site 0408), Wollongong

2800

Orange Health Services ( Site 0406), Orange

4029

Royal Brisbane and Women s Hospital ( Site 0407), Herston

4102

Princess Alexandra Hospital ( Site 0405), Woolloongabba

4814

The Townsville Hospital ( Site 0404), Douglas

5021

Haukeland Universitetssykehus ( Site 0902), Bergen

13005

Hopital La Timone ( Site 0603), Marseille

19111

Fox Chase Cancer Center ( Site 0351), Philadelphia

20007

Lombardi Comprehensive Cancer Center ( Site 0360), Washington D.C.

24105

Universitaets-Hautklinik Kiel ( Site 0656), Kiel

28034

Hospital Universitario Ramon y Cajal ( Site 0753), Madrid

30625

Medizinische Hochschule Hannover ( Site 0652), Hanover

31000

Centro Estatal de Cancerologia de Chihuahua ( Site 0308), Chihuahua City

31059

IUCT - Oncopole ( Site 0604), Toulouse

44200

Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0301), Guadalajara

45147

Universitaetsklinikum Essen ( Site 0650), Essen

46014

Hospital General de Valencia ( Site 0752), Valencia

46202

Indiana University Melvin and Bren Simon Cancer Center ( Site 0353), Indianapolis

51092

CHU Reims - Hopital Robert Debre ( Site 0610), Reims

57104

Sanford Cancer Center Oncology Clinic ( Site 0356), Sioux Falls

59037

CHRU Lille - Hopital Claude Huriez ( Site 0605), Lille

64000

Hospital y Clinica OCA SA de CV/Monterrey International ResearchCenter ( Site 0306), Monterrey

66205

University of Kansas Cancer Center ( Site 0361), Westwood

68167

Universitaetsklinikum Mannheim GmbH ( Site 0654), Mannheim

69310

CH Lyon Sud Hospices Civils de Lyon ( Site 0600), Pierre-Bénite

72076

Universitatsklinikum Tübingen ( Site 0651), Tübingen

74146

Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0364), Tulsa

75010

Hopital Saint-Louis ( Site 0601), Paris

75246

Texas Oncology PA ( Site 8000), Dallas

87042

CHU Limoges CHU Dupuytren ( Site 0608), Limoges

89148

Comprehensive Cancer Centers of Nevada ( Site 8001), Las Vegas

93009

Hopital Avicenne ( Site 0609), Bobigny

94305

Stanford University Medical Center ( Site 0366), Palo Alto

94805

Institut Gustave Roussy (IGR) ( Site 0602), Villejuif

95403

St. Joseph Heritage Healthcare ( Site 0350), Santa Rosa

3109601

Rambam Health Care Campus ( Site 0950), Haifa

4963211

Rabin Medical Center ( Site 0952), Petah Tikva

5266202

Sheba Medical Center ( Site 0953), Ramat Gan

6423906

Sourasky Medical Center. ( Site 0951), Tel Aviv

92093-0880

Moores UC San Diego Cancer Center ( Site 0352), La Jolla

06520

Yale University ( Site 0365), New Haven

02114

Massachusetts General Hospital ( Site 0362), Boston

07601

John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0367), Hackensack

E1C 8X3

Dr. Leon Richard Oncology Centre ( Site 0100), Moncton

K1H 8L6

The Ottawa Hospital Cancer Centre ( Site 0101), Ottawa

M4N 3M5

Sunnybrook Research Institute ( Site 0105), Toronto

M5G 2M9

Princess Margaret Cancer Centre ( Site 0102), Toronto

H3T 1E2

Jewish General Hospital ( Site 0103), Montreal

06202

Hopital Archet 3 ( Site 0607), Nice

03310

Grupo Medico Camino SC ( Site 0300), Mexico City

0379

Oslo Universitetssykehus Radiumhospitalet ( Site 0901), Oslo

08908

Hospital Duran i Reinals ICO de Hospitalet ( Site 0751), Hospitalet Del Llobregat

08035

Hospital Vall D Hebron ( Site 0750), Barcelona

08036

Hospital Clinic i Provincial Barcelona ( Site 0754), Barcelona

CH63 4JY

The Clatterbridge Cancer Centre NHS Foundation Trust ( Site 0803), Bebington

NW1 2PG

University College Hospital NHS Foundation Trust ( Site 0801), London

SW3 6JJ

Royal Marsden NHS Foundation Trust ( Site 0800), London

TR1 3LQ

Royal Cornwall Hospitals NHS Trust ( Site 0804), Truro

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03284424 - Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629) | Biotech Hunter | Biotech Hunter